Edition:
India

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

56.36USD
23 Oct 2020
Change (% chg)

$-0.14 (-0.25%)
Prev Close
$56.50
Open
$56.50
Day's High
$56.75
Day's Low
$55.39
Volume
141,110
Avg. Vol
289,487
52-wk High
$87.50
52-wk Low
$39.96

Latest Key Developments (Source: Significant Developments)

Global Blood Therapeutics Q2 Loss Per Share $1.01
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - Global Blood Therapeutics Inc ::GBT REPORTS RECENT BUSINESS PROGRESS AND SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $1.01.Q2 EARNINGS PER SHARE ESTIMATE $-0.96 -- REFINITIV IBES DATA.  Full Article

Global Blood Therapeutics Announces Proposed Public Offering Of Common Stock
Wednesday, 26 Jun 2019 

June 25 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.GLOBAL BLOOD THERAPEUTICS INC - AGREEMENT TO SELL APPROXIMATELY $200.0 MILLION IN SHARES OF ITS COMMON STOCK IN A REGISTERED UNDERWRITTEN PUBLIC OFFERING.GLOBAL BLOOD THERAPEUTICS - TO USE NET PROCEEDS FROM OFFERING, EXISTING CAPITAL RESOURCES TO FUND CLINICAL DEVELOPMENT OF VOXELOTOR.  Full Article

Gbt Reports Recent Business Progress And Fourth Quarter And Year-End 2018 Financial Results
Thursday, 28 Feb 2019 

Feb 27 (Reuters) - Global Blood Therapeutics Inc ::GBT REPORTS RECENT BUSINESS PROGRESS AND FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.93.Q4 EARNINGS PER SHARE ESTIMATE $-0.89 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $591.8 MILLION AT DECEMBER 31, 2018.  Full Article

Global Blood Therapeutics announces proposed public offering of common stock
Friday, 7 Dec 2018 

Dec 6 (Reuters) - Global Blood Therapeutics Inc ::GLOBAL BLOOD THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.GLOBAL BLOOD THERAPEUTICS INC SAYS ANNOUNCED AGREEMENT TO SELL $150 MILLION IN SHARES OF COMMON STOCK IN REGISTERED UNDERWRITTEN PUBLIC OFFERING.GLOBAL BLOOD THERAPEUTICS -TO USE OFFERING PROCEEDS, EXISTING CAPITAL RESOURCES TO FUND CLINICAL DEVELOPMENT OF VOXELOTOR TO TREAT SICKLE CELL DISEASE.  Full Article

Gbt Announces Positive 24-Week Results From Phase 3 HOPE Study
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Global Blood Therapeutics Inc ::GBT ANNOUNCES POSITIVE 24-WEEK RESULTS FROM PHASE 3 HOPE STUDY DEMONSTRATING CLINICALLY AND STATISTICALLY SIGNIFICANT IMPROVEMENTS IN HEMOGLOBIN AND CLINICAL MEASURES OF HEMOLYSIS AND A FAVORABLE SAFETY PROFILE.GLOBAL BLOOD THERAPEUTICS INC - INTERIM ANALYSIS OF DATA FROM 1500 MG COHORT OF HOPE-KIDS 1 STUDY CONSISTENT WITH PHASE 3 HOPE- RESULTS.GLOBAL BLOOD THERAPEUTICS INC - CONTINUING TO GENERATE EFFICACY AND SAFETY DATA ON AN ADDITIONAL 118 PATIENTS IN HOPE STUDY.GLOBAL BLOOD THERAPEUTICS INC - THERE WERE NO DRUG-RELATED DISCONTINUATIONS DUE TO ADVERSE EVENTS.GLOBAL BLOOD THERAPEUTICS INC - THERE WAS NO EVIDENCE OF IMPAIRMENT OF TISSUE OXYGENATION..  Full Article

BRIEF-GBT Announces Plans To Seek Regulatory Approval For Oxbryta To Treat Sickle Cell Patients In Europe

* GBT ANNOUNCES PLANS TO SEEK REGULATORY APPROVAL FOR OXBRYTA® (VOXELOTOR) TO TREAT SICKLE CELL PATIENTS IN EUROPE